IEHP’s UM Guideline Review Committee has approved the following authorization guideline updates/changes, effective April 26, 2022:

<table>
<thead>
<tr>
<th>Guideline #</th>
<th>Guideline Title</th>
<th>Degree of Change</th>
<th>Updates/Changes</th>
</tr>
</thead>
</table>
| UM_BH 06    | Criteria for Multidisciplinary Diagnostic Treatment | Revised Minor | Highlights:  
- No updates to report  
- Criteria remains same  
- Updated all access dates to 2022  
- Removed Medi-Cal provider manual citation |
| UM_SUR 06   | Natural Orifice Transluminal Endoscopic Surgery (NOTES) | Revised Minor | Highlights:  
- A form of surgery where an endoscope is introduced into a natural body orifice (mouth, anus, vagina, etc.), thereby eliminating the need for incisions and the resulting scars incisions produce.  
- In some cases, an incision may be made in a hollow organ to access another, nearby organ. For example, the appendix may be accessed through the stomach.  
- IEHP does not cover Natural Orifice Transluminal Endoscopic Surgery (NOTES) as a benefit. An exception is Transoral Incisionless Fundoplication (TIF) which is covered for Medicare patients for a limited number of indications.  
- Medi-Cal does not speak of this type of surgery |
<table>
<thead>
<tr>
<th>Guideline #</th>
<th>Guideline Title</th>
<th>Degree of Change</th>
<th>Updates/Changes</th>
</tr>
</thead>
</table>
| UM_OTH 21   | Chimeric Antigen Receptor T Cell Therapy (CAR-T) | Revised Moderate | Highlights:  
  - CAR-T therapy involves reprogramming a patient’s own T cells with a transgene encoding a chimeric antigen receptor (CAR) to target CD19-expressing malignant cells in various various hematological malignancies  
  - There are 6 FDA-approved drugs on the market  
    o Kymriah (tisagenlecleucel)  
    o Yescarta (axicabtagene ciloleucel)  
    o Tecartus (brexucabtagene autoleucel)  
    o Breyanzi (lisocabtagene maraleucel)  
    o Abecma (idecabtagene vicleucel)  
    o Carvykti (ciltaabtagene autoleucel) - Approved February 2022 (NEW)  
  - Update IEHP CAR-T Policy (UM_OTH 21) to address the expanding class  
    o NCCN guidelines, Package Insert, Patient Clinical Status, Quantity Limit |
| UM_OTH 20   | Spravato        | Retired         | Highlights:  
  - Spravato is a CIII nasal spray used for treatment-resistant MDD and MDD with acute suicidal ideation or behavior  
  - Retire IEHP Spravato Policy (UM_OTH 20)  
    o Spravato must be administered and dispensed as dictated by its Risk Evaluation and Mitigation Strategy (REMS) program  
    o DHCS released updated guidelines for use that overlap with current IEHP policy |

You may access these and all other authorization guidelines through the Provider portal:
www.iehp.org > For Providers > Utilization Management Criteria

If you have any questions, please do not hesitate to contact the IEHP Provider Relations Team at (909) 890-2054 or (866) 223-4347.